Back to today’s briefing

Story perspectives

Acorda Therapeutics' $16.5M Appeal Transferred to Second Circuit

7/28/2025

50 6

Summary

Story summary

Acorda Therapeutics faces a setback as the U.S. Court of Appeals for the Federal Circuit has transferred its appeal over a $16.5 million arbitral award to the Second Circuit. The court determined that Acorda's claims did not sufficiently involve patent law, thus falling short of the federal jurisdiction requirements outlined in the Gunn test.

1 of 1

Story summary

Acorda Therapeutics faces a setback as the U.S. Court of Appeals for the Federal Circuit has transferred its appeal over a $16.5 million arbitral award to the Second Circuit. The court determined that Acorda's claims did not sufficiently involve patent law, thus falling short of the federal jurisdiction requirements outlined in the Gunn test.